Patrick J. Balthrop Sr.

Overview

Patrick J. Balthrop Sr. is a seasoned executive with extensive experience in the healthcare and biotechnology sectors, specializing in diagnostics and life sciences. He served as President and CEO of Luminex Corporation from 2004 to 2014, during which time the company's revenues grew eightfold. Under his leadership, Luminex developed and commercialized numerous innovative products, significantly expanding its international presence and product portfolio. Prior to Luminex, Mr. Balthrop was President of Fisher Healthcare and held various leadership positions at Abbott Laboratories, including head of worldwide commercial diagnostics operations and head of Abbott Vascular. He currently serves as Chairman of the Board of Agendia, Inc., a personalized medicine and molecular cancer diagnostics company, and as Chairman of the Board of Discovery Life Sciences, a provider of research services and biospecimen solutions to the life sciences industry. Additionally, he is a director of MaxCyte, Inc., a company specializing in cell and gene therapy enabling technologies. Mr. Balthrop holds a Bachelor of Science in Biology from Spring Hill College and an MBA from the Kellogg School of Management at Northwestern University. Throughout his career, Mr. Balthrop has demonstrated a strong commitment to advancing healthcare through innovation and strategic leadership. His tenure at Luminex was marked by significant growth and the successful commercialization of new products, earning the company recognition as one of the fastest-growing technology companies in America. His leadership at Agendia and Discovery Life Sciences reflects his ongoing dedication to the life sciences sector, focusing on personalized medicine and research services. His role at MaxCyte underscores his involvement in cutting-edge cell and gene therapy technologies, highlighting his broad expertise in the biotechnology field. Mr. Balthrop's extensive experience and leadership in the healthcare and biotechnology sectors have positioned him as a key figure in advancing diagnostics and life sciences. His strategic vision and commitment to innovation continue to influence the industry, contributing to the development of new technologies and therapies that enhance patient care and scientific research.